成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. PI3K/Akt/mTOR Autophagy
  2. Akt Autophagy
  3. Capivasertib

Capivasertib  (Synonyms: AZD5363)

目錄號: HY-15431 純度: 99.95%
COA 產(chǎn)品使用指南 技術(shù)支持

Capivasertib (AZD5363) 是一種口服有效的 pan-AKT 激酶抑制劑,抑制 Akt1Akt2Akt3,IC50 分別為 3,7 和 7 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

Capivasertib Chemical Structure

Capivasertib Chemical Structure

CAS No. : 1143532-39-1

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機構(gòu)(單位)一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥896
In-stock
1 mg ¥411
In-stock
5 mg ¥950
In-stock
10 mg ¥1400
In-stock
25 mg ¥2280
In-stock
50 mg ¥3200
In-stock
100 mg ¥4913
In-stock
500 mg 現(xiàn)貨 詢價
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Capivasertib:

MCE 顧客使用本產(chǎn)品發(fā)表的 59 篇科研文獻

WB

    Capivasertib purchased from MCE. Usage Cited in: Autophagy. 2021 Jun;17(6):1349-1366.  [Abstract]

    MiaPaca2 cells are treated with 25 μM AZD5363 (AKT inhibitor), 0.1 μM AZD2014 (MTOR inhibitor) for 24 h. Expression of RPS6, p-RPS6, lipidated and non-lipidated MAP1LC3B and ACTB proteins are determined by immunoblotting.

    查看 Akt 亞型特異性產(chǎn)品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.

    IC50 & Target[1]

    Akt1

    3 nM (IC50)

    Akt2

    7 nM (IC50)

    Akt3

    7 nM (IC50)

    P70S6K

    6 nM (IC50)

    PKA

    7 nM (IC50)

    ROCK2

    60 nM (IC50)

    ROCK1

    470 nM (IC50)

    Autophagy

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    769-P IC50
    10.75 μM
    Compound: AZD5363
    Antiproliferative activity against human 769-P cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human 769-P cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    786-0 IC50
    23.28 μM
    Compound: AZD5363
    Antiproliferative activity against human 786-0 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human 786-0 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    A549 IC50
    23.67 μM
    Compound: AZD5363
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    AGS IC50
    9.6 μM
    Compound: AZD5363
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34917257]
    Bel-7402 IC50
    49.6 μM
    Compound: AZD5363
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    CHO IC50
    > 100000 nM
    Compound: 64, AZD5363
    Inhibition of human ERG expressed in CHO cells by ionworks assay
    Inhibition of human ERG expressed in CHO cells by ionworks assay
    [PMID: 23394218]
    HaCaT IC50
    4.2 μM
    Compound: AZD5363
    Antiproliferative activity against human HaCaT cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human HaCaT cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    [PMID: 34375113]
    HCT-116 IC50
    5.2 μM
    Compound: AZD5363
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    [PMID: 31298542]
    HCT-116 IC50
    5.2 μM
    Compound: AZD5363
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    [PMID: 27089211]
    HepG2 IC50
    6.7 μM
    Compound: AZD5363
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    HT-29 IC50
    36.92 μM
    Compound: AZD5363
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    KHOS/NP IC50
    40.42 μM
    Compound: AZD5363
    Antiproliferative activity against human KHOS cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human KHOS cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    LNCaP IC50
    0.46 μM
    Compound: AZD5363
    Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    LNCaP IC50
    336.8 nM
    Compound: AZD5363
    Inhibition of Akt in human PTEN-null LNCAP cells assessed as suppression in PRAS40 phosphorylation after 1 hr by ELISA analysis
    Inhibition of Akt in human PTEN-null LNCAP cells assessed as suppression in PRAS40 phosphorylation after 1 hr by ELISA analysis
    [PMID: 27089211]
    MCF7 IC50
    4.2 μM
    Compound: AZD5363
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34917257]
    MDA-MB-231 IC50
    60.52 μM
    Compound: AZD5363
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    MDA-MB-468 GI50
    3.8 μM
    Compound: AZD5363
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth by measured after 5 days by IncuCyte zoom live cell analysis
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth by measured after 5 days by IncuCyte zoom live cell analysis
    [PMID: 35119851]
    MDA-MB-468 IC50
    89 nM
    Compound: 64, AZD5363
    Inhibition of Akt in human MDA-MB-468 cells assessed as inhibition of GSK3beta phosphorylation after 2 hrs by laser scanning cytometry
    Inhibition of Akt in human MDA-MB-468 cells assessed as inhibition of GSK3beta phosphorylation after 2 hrs by laser scanning cytometry
    [PMID: 23394218]
    NCI-H1975 IC50
    2.7 μM
    Compound: AZD5363
    Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34917257]
    NCI-H1975 IC50
    8.23 μM
    Compound: AZD5363
    Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    OS-RC-2 IC50
    53.43 μM
    Compound: AZD5363
    Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    OVCAR-8 IC50
    4.48 μM
    Compound: AZD5363
    Antiproliferative activity against human OVCAR-8 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human OVCAR-8 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    OVCAR-8 IC50
    7.27 μM
    Compound: AZD5363
    Antiproliferative activity against human OVCAR8 cells after 72 hrs by SRB assay
    Antiproliferative activity against human OVCAR8 cells after 72 hrs by SRB assay
    [PMID: 27089211]
    PC-3 GI50
    6.5 μM
    Compound: AZD5363
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 5 days by IncuCyte zoom live cell analysis
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 5 days by IncuCyte zoom live cell analysis
    [PMID: 35119851]
    PC-3 IC50
    82.57 μM
    Compound: AZD5363
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    SK-OV-3 IC50
    6.32 μM
    Compound: AZD5363
    Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    SMMC-7721 IC50
    84.12 μM
    Compound: AZD5363
    Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    U-251 IC50
    14.22 μM
    Compound: AZD5363
    Antiproliferative activity against human U251 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human U251 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    U-87MG ATCC IC50
    50.6 μM
    Compound: AZD5363
    Antiproliferative activity against human U-87MG cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    Antiproliferative activity against human U-87MG cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method
    [PMID: 34375113]
    體外研究
    (In Vitro)

    Capivasertib 可抑制所有 AKT 同工酶,效力為 10 nM 或更低。Capivasertib 可抑制這些底物的磷酸化,在 3 種細(xì)胞系中的 IC50 值為 0.06 至 0.76 μM。Capivasertib 可有效抑制這些細(xì)胞系中 S6 和 4E-BP1 的磷酸化,同時增加 ser473 和 thr308AKT 的磷酸化。在 BT474c 細(xì)胞中,Capivasertib 可誘導(dǎo) FOXO3a 核轉(zhuǎn)位,EC50 值為 0.69 μM;3 μM 的濃度足以幾乎完全將 FOXO3a 定位到細(xì)胞核中[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內(nèi)研究
    (In Vivo)

    裸鼠口服 Capivasertib (AZD5363) 會導(dǎo)致 BT474c 異種移植瘤中的 PRAS40、GSK3β 和 S6 磷酸化呈劑量和時間依賴性降低(PRAS40 磷酸化 EC50 ~0.1 μM 總血漿暴露量),血糖濃度可逆性升高,U87-MG 異種移植瘤中 2[18F]氟-2-脫氧-D-葡萄糖 (18F-FDG) 攝取量呈劑量依賴性降低。長期口服 Capivasertib 會導(dǎo)致來自各種腫瘤類型(包括 HER2+ 乳腺癌模型)的異種移植瘤出現(xiàn)劑量依賴性生長抑制。 Capivasertib 還顯著增強了 RP-56976 和 GW572016 在乳腺癌異種移植中的抗腫瘤活性[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    428.92

    Formula

    C21H25ClN6O2

    CAS 號
    性狀

    固體

    顏色

    Off-white to gray

    運輸條件

    Room temperature in continental US; may vary elsewhere.

    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實驗: 

    DMSO 中的溶解度 : 125 mg/mL (291.43 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響,請使用新開封的 DMSO)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.3314 mL 11.6572 mL 23.3144 mL
    5 mM 0.4663 mL 2.3314 mL 4.6629 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲存時,請在1年內(nèi)使用, -20°C儲存時,請在6個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗:

    請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
    ——為保證實驗結(jié)果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實驗的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.85 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.85 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

      2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
    動物溶解方案計算器
    請輸入動物實驗的基本信息:

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    由于實驗過程有損耗,建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購。 Tween 80,均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上,請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.95%

    參考文獻
    Cell Assay
    [1]

    Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates (at a density to allow for logarithmic growth during the 72-hour assay) and incubated overnight at 37°C, 5% CO2. Cells are then exposed to concentrations of Capivasertib ranging from 30 to 0.003 μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent. Absorbance is measured with a Tecan Ultra instrument. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells (GI50) values are determined using absorbance readings (MTS) or live cell counts[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    Specific, pathogen-free, female nude mice (nu/nu: Alpk) and male SCID mice (SCID/CB17; 786-0 xenograft studies) are used. When mean tumor sizes reach approximately 0.2 cm3, the mice are randomized into control and treatment groups. The treatment groups received varying dose schedules of Capivasertib (AZD5363) solubilized in a 10% DMSO 25% w/v Kleptose HPB (Roquette) buffer by oral gavage, RP-56976 solubilized in 2.6% ethanol in injectable water by intravenous injection once on day 1 at 15 or 5 mg/kg once weekly. When administered in combination, RP-56976 is administered 1 hour before the oral dose of Capivasertib (AZD5363). The control group received the DMSO/Kleptose buffer alone, twice daily by oral gavage. Tumor volumes (measured by caliper), animal body weight, and tumor condition are recorded twice weekly for the duration of the study. Mice are sacrificed by CO2 euthanasia. The tumor volume is calculated (taking length to be the longest diameter across the tumor and width to be the corresponding perpendicular diameter) using the formula: (length×width)×√(length×width)×(π/6). Growth inhibition from the start of treatment is assessed by comparison of the differences in tumor volume between control and treated groups.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲存時,請在1年內(nèi)使用, -20°C儲存時,請在6個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3314 mL 11.6572 mL 23.3144 mL 58.2859 mL
    5 mM 0.4663 mL 2.3314 mL 4.6629 mL 11.6572 mL
    10 mM 0.2331 mL 1.1657 mL 2.3314 mL 5.8286 mL
    15 mM 0.1554 mL 0.7771 mL 1.5543 mL 3.8857 mL
    20 mM 0.1166 mL 0.5829 mL 1.1657 mL 2.9143 mL
    25 mM 0.0933 mL 0.4663 mL 0.9326 mL 2.3314 mL
    30 mM 0.0777 mL 0.3886 mL 0.7771 mL 1.9429 mL
    40 mM 0.0583 mL 0.2914 mL 0.5829 mL 1.4571 mL
    50 mM 0.0466 mL 0.2331 mL 0.4663 mL 1.1657 mL
    60 mM 0.0389 mL 0.1943 mL 0.3886 mL 0.9714 mL
    80 mM 0.0291 mL 0.1457 mL 0.2914 mL 0.7286 mL
    100 mM 0.0233 mL 0.1166 mL 0.2331 mL 0.5829 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱:

     

    * 需求量:

    * 客戶姓名:

     

    * Email:

    * 電話:

     

    * 公司或機構(gòu)名稱:

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱:
    Capivasertib
    目錄號:
    HY-15431
    需求量: